  Dutch biotechnology company Crucell  N.V. (Leiden, the Netherlands, 

)  and Novartis Vaccines and Diagnostics, Inc. (Basel, Switzerland, 

), have extended a  nonexclusive research license agreement for PER.C6. The license agreement  allows Novartis to use Crucell’s PER.C6 cell technology in manufacturing  alphavirus vectors for its vaccine research programs. The PER.C6 technology is  a human cell line developed for the development and large-scale manufacture of  biopharmaceutical products including vaccines.

News

Dutch biotechnology company Crucell N.V. (Leiden, the Netherlands, www.crucell.com) and Novartis Vaccines and Diagnostics, Inc. (Basel, Switzerland, www.novartis.com), have extended a nonexclusive research license agreement for PER.C6.